PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Antibiotic Substitution Ends Decade-Long NICU Tobramycin-Resistant S. aureus Outbreak

tobramycinamikacinaminoglycosidespenicillin GStaphylococcus aureusTRSAMSSANICU outbreakantimicrobial stewardshipinfection preventionspa typingantibiotic rotationretrospective study Infectious Disease / Antimicrobials
Also in Pediatrics

Background Information

Targeted interventions halted a decade-long resistant bacteria outbreak in a NICU.

The study focuses on managing a Staphylococcus aureus outbreak in neonatal intensive care units (NICUs), crucial for protecting vulnerable infants from antibiotic-resistant infections. The prevalence of tobramycin-resistant Staphylococcus aureus (TRSA) decreased significantly after implementing hygiene and antibiotic regimen changes, with no cases of TRSA septicemia post-intervention. The findings illustrate the importance of environmental controls and appropriate antibiotic use in managing resistant bacteria in NICUs. Limitations include a single-center focus and retrospective analysis. Comprehensive infection control measures successfully managed a NICU outbreak of tobramycin-resistant Staphylococcus aureus.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jogenfors A, Mernelius S, Löfgren S, Bengnér M, Bengnér J, Ingemansson F, Wetterbrandt S, Matussek A

Citation: Jogenfors A, Mernelius S, Löfgren S, et al. Combatting a Tobramycin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit: the impact of hygiene intervention and antibiotic substitution. BMC infectious diseases. 2026;26(1). doi:10.1186/s12879-026-14481-2

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.